Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: Inhibition of USP14 enhances the sensitivity of breast cancer to enzalutamide

Fig. 3

Induction of apoptosis by the co-treatment of enzalutamide and USP14 inhibition in breast cancer cells. MDA-MB453 and MCF-7 cells were treated with vehicle control (DM), enzalutamide (Enza, 20 μM), IU1 (75 μM), or the combination of both (Enza+IU1). Or MDA-MB453 cells were similarly exposed to enzalutamide (Enza or E; 20 μM), USP14 siRNA (si-; 50 nM), or the combination of both. At 48 h post-treatment, the cells were either processed for Annexin V-FITC/PI staining followed by flow cytometry (a) and (b) or harvested for western blot analyses for the indicated proteins in total cell lysates (c). GAPDH was used as a loading control. Representative histograms (a) and the percentage of cell death (b) derived from flow cytometry as well as the representative images of western blot (c) are shown. #p < 0.01 vs. each treatment alone

Back to article page